Patient Preferences for Anti-Vascular Endothelial Growth Factor Treatment for Wet Age-Related Macular Degeneration in Japan: A Discrete Choice Experiment

References

• Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392(10153):1147–1159. doi:10.1016/S0140-6736(18)31550-2
   PubMed Web of Science ®Google Scholar
• Mayo Clinic. Wet macular degeneration. Available from: https://www.mayoclinic.org/diseases-conditions/wet-macular-degeneration/symptoms-causes/syc-20351107. Accessed January 30, 2019.
   Google Scholar
• Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–e116. doi:10.1016/S2214-109X(13)70145-1
   PubMed Web of Science ®Google Scholar
• Oshima Y, Ishibashi T, Murata T, Tahara Y, Kiyohara Y, Kubota T. Prevalence of age related maculopathy in a representative Japanese population: the Hisayama study. Br J Ophthalmol. 2001;85(10):1153–1157. doi:10.1136/bjo.85.10.1153
   PubMed Web of Science ®Google Scholar
• Takahashi K, Ogura Y, Ishibashi T, Shiraga F, Yuzawa M. Treatment guidelines for age-related macular degeneration. Nihon Ganka Gakkai Zasshi. 2012;116(12):1150–1155.
   Google Scholar
• Lanzetta P, Loewenstein A. Vision academy steering committee. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255(7):1259–1273. doi:10.1007/s00417-017-3647-4
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481
   PubMed Web of Science ®Google Scholar
• Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57–65.e5. doi:10.1016/j.ophtha.2008.10.018
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Croft DE, Brown DM, et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology. 2015;122(12):2514–2522. doi:10.1016/j.ophtha.2015.08.009
   PubMed Web of Science ®Google Scholar
• Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol. 2009;148(1):43–58.e1. doi:10.1016/j.ajo.2009.01.024
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology. 2012;119(7):1388–1398. doi:10.1016/j.ophtha.2012.03.053
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration. Ophthalmology. 2012;119(7):1399–1411. doi:10.1016/j.ophtha.2012.04.015
   PubMed Web of Science ®Google Scholar
• Ho AC, Busbee BG, Regillo CD, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121(11):2181–2192. doi:10.1016/j.ophtha.2014.05.009
   PubMed Web of Science ®Google Scholar
• Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046–1056. doi:10.1016/j.ophtha.2012.10.014
   PubMed Web of Science ®Google Scholar
• van Asten F, Evers-Birkenkamp KU, van Lith-verhoeven JJC, et al. A prospective, observational, open-label, multicentre study to investigate the daily treatment practice of ranibizumab in patients with neovascular age-related macular degeneration. Acta Ophthalmol. 2015;93(2):126–133. doi:10.1111/aos.12610
   PubMed Web of Science ®Google Scholar
• Ferreira A, Sagkriotis A, Olson M, Lu J, Makin C, Milnes F. Treatment frequency and dosing interval of ranibizumab and aflibercept for neovascular age-related macular degeneration in routine clinical practice in the USA. PLoS One. 2015;10(7):e0133968. doi:10.1371/journal.pone.0133968
   PubMed Web of Science ®Google Scholar
• Mantel I. Optimizing the anti-VEGF treatment strategy for neovascular age-related macular degeneration: from clinical trials to real-life requirements. Transl Vis Sci Technol. 2015;4(3):6. doi:10.1167/tvst.4.3.6
   Web of Science ®Google Scholar
• Wolf A, Kampik A. Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol. 2014;252(4):647–655. doi:10.1007/s00417-013-2562-6
   Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548. doi:10.1016/j.ophtha.2012.09.006
   PubMed Web of Science ®Google Scholar
• Oubraham H, Cohen SY, Samimi S, et al. Inject and extend dosing versus dosing as needed. Retina. 2011;31(1):26–30. doi:10.1097/IAE.0b013e3181de5609
   PubMed Web of Science ®Google Scholar
• Silva R, Berta A, Larsen M, et al. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration. Ophthalmology. 2018;125(1):57–65. doi:10.1016/j.ophtha.2017.07.014
   PubMed Web of Science ®Google Scholar
• Haga A, Kawaji T, Ideta R, Inomata Y, Tanihara H. Treat-and-extend versus every-other-month regimens with aflibercept in age-related macular degeneration. Acta Ophthalmol. 2018;96(3):e393–e398. doi:10.1111/aos.13607
   Web of Science ®Google Scholar
• DeCroos FC, Reed D, Adam MK, et al. Treat-and-extend therapy using aflibercept for neovascular age-related macular degeneration: a prospective clinical trial. Am J Ophthalmol. 2017;180:142–150. doi:10.1016/j.ajo.2017.06.002
   PubMed Web of Science ®Google Scholar
• Barthelmes D, Nguyen V, Daien V, et al. Two year outcomes of “treat and extend” intravitreal therapy using aflibercept preferentially for neovascular age-related macular degeneration. Retina. 2018;38(1):20–28. doi:10.1097/IAE.0000000000001496
   PubMed Web of Science ®Google Scholar
• Koh A, Lanzetta P, Lee W, Lai -C-C, Chan W-M, Yang C-M. Recommended guidelines for use of intravitreal aflibercept with a treat-and-extend regimen for the management of neovascular age-related macular degeneration in the Asia-Pacific region: report from a consensus panel. Asia-Pac J Ophthalmol (Phila). 2017;6(3):296–302. doi:10.22608/APO.2016125
   PubMed Web of Science ®Google Scholar
• Iida T, Ishii K. Physician, patient, and caregiver experience of different wet age-related macular degeneration anti-VEGF treatment regimens in Japan: a qualitative assessment. Clin Ophthalmol. 2016;10:2505–2513. doi:10.2147/OPTH
   Google Scholar
• EYLEA® (aflibercept) injection approved for the treatment of wet age-related macular degeneration in Japan. Available from: https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-approved-treatment-wet-age-0. Accessed August 7, 2019.
   Google Scholar
• Lindhiem O, Bennett CB, Trentacosta CJ, McLear C. Client preferences affect treatment satisfaction, completion, and clinical outcome: a meta-analysis. Clin Psychol Rev. 2014;34(6):506–517. doi:10.1016/j.cpr.2014.06.002
   PubMed Web of Science ®Google Scholar
• Hughes TM, Merath K, Chen Q, et al. Association of shared decision-making on patient-reported health outcomes and healthcare utilization. Am J Surg. 2018;216(1):7–12. doi:10.1016/j.amjsurg.2018.01.011
   PubMed Web of Science ®Google Scholar
• Hack TF, Degner LF, Watson P, Sinha L. Do patients benefit from participating in medical decision making? Longitudinal follow-up of women with breast cancer. Psychooncology. 2006;15(1):9–19. doi:10.1002/(ISSN)1099-1611
   PubMed Web of Science ®Google Scholar
• Schoenthaler A, Rosenthal DM, Butler M, Jacobowitz L. Medication adherence improvement similar for shared decision-making preference or longer patient-provider relationship. J Am Board Fam Med. 2018;31(5):752–760. doi:10.3122/jabfm.2018.05.180009
   PubMed Web of Science ®Google Scholar
• Droege KM, Muether PS, Hermann MM, et al. Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life. Graefes Arch Clin Exp Ophthalmol. 2013;251(5):1281–1284. doi:10.1007/s00417-012-2177-3
   PubMed Web of Science ®Google Scholar
• Mueller S, Agostini H, Ehlken C, Bauer-Steinhusen U, Hasanbasic Z, Wilke T. Patient preferences in the treatment of neovascular age-related macular degeneration. Ophthalmology. 2016;123(4):876–883. doi:10.1016/j.ophtha.2015.12.001
   PubMed Web of Science ®Google Scholar
• Baxter JM, Fotheringham AJ, Foss AJE. Determining patient preferences in the management of neovascular age-related macular degeneration: a conjoint analysis. Eye (Lond). 2016;30(5):698–704. doi:10.1038/eye.2016.18
   PubMed Web of Science ®Google Scholar
• Mangham LJ, Hanson K, McPake B. How to do (or not to do) … Designing a discrete choice experiment for application in a low-income country. Health Policy Plan. 2009;24(2):151–158. doi:10.1093/heapol/czn047
   PubMed Web of Science ®Google Scholar
• Bridges JFP, Hauber AB, Marshall D, et al. Conjoint analysis applications in health—a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14(4):403–413. doi:10.1016/j.jval.2010.11.013
   PubMed Web of Science ®Google Scholar
• Ministry of Education, Culture, Sports, Science and Technology, and Ministry of Health, Labour and Welfare, Japan. Ethical Guidelines for Medical and Health Research Involving Human Subjects. Tokyo, Japan; 2015.
   Google Scholar
• Berg K, Pedersen TR, Sandvik L, Bragadóttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015;122(1):146–152. doi:10.1016/j.ophtha.2014.07.041
   PubMed Web of Science ®Google Scholar
• Rayess N, Houston SKS, Gupta OP, Ho AC, Regillo CD. Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. Am J Ophthalmol. 2015;159(1):3–8.e1. doi:10.1016/j.ajo.2014.09.011
   Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the Charlson Comorbidity Index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682. doi:10.1093/aje/kwq433
   PubMed Web of Science ®Google Scholar
• Kuhfeld WF. Marketing Research Methods in SAS. Experimental Design, Choice, Conjoint, and Graphical Techniques. Cary, NC, USA; 2010.
   Google Scholar
• Hauber AB, González JM, Groothuis-Oudshoorn CGM, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19(4):300–315. doi:10.1016/j.jval.2016.04.004
   PubMed Web of Science ®Google Scholar
• Brown MM, Brown GC, Sharma S, Landy J, Bakal J. Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol. 2002;120(4):481–484. doi:10.1001/archopht.120.4.481
   PubMedGoogle Scholar
• Vennedey V, Danner M, Evers SM, et al. Using qualitative research to facilitate the interpretation of quantitative results from a discrete choice experiment: insights from a survey in elderly ophthalmologic patients. Patient Prefer Adherence. 2016;10:993–1002. doi:10.2147/PPA
   PubMed Web of Science ®Google Scholar
• Okada M, Kandasamy R, Chong EW, McGuiness M, Guymer RH. The treat-and-extend injection regimen versus alternate dosing strategies in age-related macular degeneration: a systematic review and meta-analysis. Am J Ophthalmol. 2018;192:184–197. doi:10.1016/j.ajo.2018.05.026
   PubMed Web of Science ®Google Scholar
• Rufai SR, Almuhtaseb H, Paul RM, et al. A systematic review to assess the ‘treat-and-extend’ dosing regimen for neovascular age-related macular degeneration using ranibizumab. Eye. 2017;31(9):1337–1344. doi:10.1038/eye.2017.67
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Ou WC, Brown DM, et al. Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-year results of the TREX-AMD study. Ophthalmol Retina. 2017;1(4):314–321. doi:10.1016/j.oret.2016.12.004
   Google Scholar
• Ohji M, Okada AA, Takahashi K, Kobayashi M, Terano Y. Two different treat-and-extend dosing regimens of intravitreal aflibercept in Japanese patients with wet age-related macular degeneration: 96 week results of the ALTAIR study. In 18th EURETINA Congress. September 20–23 2018; Vienna, Austria.
   Google Scholar
• Ohji M, Okada AA, Takahashi K, Kobayashi M, Terano Y. Two different treat and extend dosing regimens of intravitreal aflibercept for wAMD in Japanese patients: 52 weeks results of the ALTAIR study. In 17th EURETINA Congress. September 7–10 2017; Barcelona, Spain.
   Google Scholar
• Stuart A The whys and hows of shared decision making. EyeNet Magazine. January, 2015:27–28. doi:10.3389/fped.2015.00027
   Google Scholar
• Wai KM, Singh RP. Treat and extend dosing regimen with anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Am J Ophthalmic Clin Trials. 2018;1(1):1–6. doi:10.25259/AJOCT-2-2018
   Google Scholar
• Iida T, Narimatsu A, Adachi K, Wang EC. Anti-vascular endothelial growth factor outpatient treatment patterns in patients with exudative age-related macular degeneration from a Japanese hospital claims database. J Health Econ Outcomes Res. 2014;2(1):41–52.
   Google Scholar
• Talks JS, Lotery AJ, Ghanchi F, et al. First-year visual acuity outcomes of providing aflibercept according to the VIEW study protocol for age-related macular degeneration. Ophthalmology. 2016;123(2):337–343. doi:10.1016/j.ophtha.2015.09.039
   Web of Science ®Google Scholar
• Uemura H, Matsubara N, Kimura G, et al. Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment. BMC Urol. 2016;16(1):63. doi:10.1186/s12894-016-0182-2
   PubMed Web of Science ®Google Scholar
• CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–1908.
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–1444. doi:10.1056/NEJMoa062655
   PubMed Web of Science ®Google Scholar
• Abedi F, Wickremasinghe S, Islam AFM, Inglis KM, Guymer RH. Anti-VEGF treatment in neovascular age-related macular degeneration. Retina. 2014;34(8):1531–1538. doi:10.1097/IAE.0000000000000134
   PubMed Web of Science ®Google Scholar